contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Suominen is a manufacturing company. The company manufactures and develops a wide range of wipes, hygiene products and medical applications. The manufacturing is based on non-woven fabrics that can be used for various purposes. Customers are found in several industries, with the largest operations in Europe and North America. The company has its headquarters in Helsinki.

Rauli has published a new company report on Suominen following Q4  Suominen’s Q4 figures were clearly weaker than our forecasts. In line with our expectations, the company announced a new multi-year and extensive efficiency program that supports our forecasted earnings growth for the coming years. However, in our view, the stock’s valuation is already pricing in a level of earnings better than our forecasts for the next few years. We estimate that, in addition to this, the company may need equity financing to implement the efficiency program and support the balance sheet. We are lowering the target price to EUR 1.3 (prev. EUR 1.6) due to the weakened forecasts and updating our recommendation to Sell (prev. Reduce).                   Inderes              Suominen Q4'25: Tase voi vaatia korjausta tänä vuonna - Inderes    Suomisen Q4-luvut olivat selvästi ennusteitamme heikommat.

A miserable Q4 from Suominen today: revenue fell sharply and adj. EBITDA was less than half of expectations. As expected, the company announced a much-needed new and broader efficiency program. Below are comments from CEO Heaulme; more of our thoughts will follow in tomorrow’s report.                   Inderes              Suominen Q4’25: Profitability improvement program - Inderes    Aika: 29.01.2026 klo 14.08 CEO Charles Héaulmé goes through the main topics of Suominen’s year 2025 and future plans.

Let’s mention here that since the current Chairman of the Board, Heaulme, has stepped up as CEO, the leadership of the board will naturally change at the spring Annual General Meeting. Joining the board as a new member to take on the role is Ville Vuori, who is currently the Chairman of Aspocomp and Incap. A figure unknown to me, at least. CEO Heaulme already promised in the Q3 interview that some new efficiency measures would be coming on a relatively fast schedule (this could well be in connection with Thursday’s results), with a strategy update following in the summer. Thus, the new Chairman will be joining these processes mid-way, and the initiative in them seems to rest with Heaulme and his team. By the way, there will be the usual CEO interview in connection with Thursday’s Q4 results – if you have any questions, feel free to send them our way. In the Q3 interview, we already covered quite a lot of Charles’s general views on Suominen.                   Inderes              Osakkeenomistajien nimitystoimikunnan ehdotukset Suomisen varsinaiselle...    Suominen Oyj:n pörssitiedote 26.1.2026 klo 13.00 Ehdotus hallituksen jäsenten lukumäärästä, hallituksen jäsenistä ja puheenjohtajasta Osakkeenomistajien nimitystoimikunta ehdottaa varsinaiselle...

Here are the preview comments from Rauli ahead of Suominen’s Q4 result on Jan 29.  Suominen will report its Q4 results on Thursday, January 29, 2026. We expect the company’s year-end result to have remained weak, as the production issues that emerged in Q3 were still partly reflected in the final quarter. The main focus of the report will, however, be on 2026 and the measures potentially presented by CEO Charles Héaulme to turn profitability back towards growth. We expect the company to guide for an improved result for 2026.                   Inderes              Suominen Q4’25 -ennakko: Katseet kääntyvät uusiin lääkkeisiin tuloksen...    Suominen raportoi Q4-tuloksensa torstaina 29.1.2026.  Raportin päähuomio kiinnittyy  vuoteen 2026 ja toimitusjohtaja Charles Héaulmen mahdollisesti esittelemiin toimenpiteisiin kannattavuuden kääntämiseksi nousuun.

I agree, and it’s definitely worth listening to if Suominen interests you at all. I don’t know if even Charles can turn this around, but at least he seems to have a good grip, and new, perhaps big, actions are coming. We’ll see in the coming years how far they go.

Rauli has prepared a new company report following Suominen’s Q3.   Suominen’s Q3 report contained limited new information after the preliminary data and guidance cut provided by the company two weeks ago. The new CEO will launch some kind of profitability program. In our opinion, this is necessary, considering the company’s loss-making earnings level. However, we believe the company’s valuation already prices in a higher earnings level than our forecasts, and thus the return expectation remains weak. We reiterate our Reduce recommendation and a target price of 1.6 euros. Quoted from the report: Price already reflects better-than-expected performance We value Suominen using earnings and balance sheet-based multiples and a DCF model. The earnings improvement we forecast will go into digesting the multiples in the coming years, and even with a significantly better earnings level (2027), we consider the valuation high. With the dividend being zero in the coming years, it also does not offer support for the return expectation. Thus, we see the return expectation as weak.                   Inderes              Suominen Q3'25: Uusia kannattavuustoimia tulossa - Inderes    Suomisen Q3-raportti sisälsi rajallisesti uutta tietoa yhtiön pari viikkoa sitten antamien ennakkotietojen ja ohjeistuksen laskun jälkeen.

An impressive performance by Charles Héaulmé. It instilled confidence in the future. I bought Suominen shares. Seems like a good value - strong presence in the USA. I see that as a strength.

Suominen

Today, Suominen announced imminent change of the CEO. Mr. Charles Héaulmé, current Chair of the Board, has been appointed as the new CEO latest from 11 August 2025. Latest, Mr. Héaulmé acted...

Today, Suominen announced imminent change of the CEO. Mr. Charles Héaulmé, current Chair of the Board, has been appointed as the new CEO latest from 11 August 2025. Latest, Mr. Héaulmé acted as CEO of Huhtamäki while worked before that in Tetra Pak for 20 years. We view Mr. Héaulmé as a good fit for Suominen with relevant experience from converter businesses. We note Suominen is at the end of its current strategy period and the change of CEO  could indicate larger changes to the current strategy. Mr. Tommi Björnman will step down from the position of CEO as of today and the current CFO, Mr. Janne Silonsaari is appointed as interim CEO. Mr. Héaulmé will continue to serve as Chair of the Board until the next AGM of Suominen. In addition to possible larger strategy changes, we believe the change of CEO increases profit warning risk to some extent. We currently model 2025E comparable EBITDA of EUR  21m, 9% below Vara Research consensus and up 22% from EUR 17m in 2024 while Suominen expects its comparable EBITDA to increase y/y in 2025.